Inclusion Criteria:

- Patients with histologically confirmed lung cancer, who complain of cancer pain

- Patients who are taking Ultracet, Tramadol, or Codeine (or Codeine combination drug)
for cancer pain-relief purposes, but still complain of a pain level of 4 or above on
the Numeric Rating Scale (NRS) during the past 24 hours: Ultracet 3 tablets/day,
Tramadol 150 mg/day, Codeine 200 mg /day, or Codeine combination less than 3
capsules/day

- Patients who are able to communicate with the investigator about his/her pain

- Patients who use proper contraceptives during the study period if they are women of
childbearing potential

- Patients whose life expectancy is 3 months or longer

- Patients who have signed an informed consent form

Exclusion Criteria:

- Patients participating in other clinical trials

- Patients with a history of hypersensitivity to opioid analgesics

- Patients with a history of drug abuse

- Patients who are unable to use a transdermal product due to skin disease

- Patient with a history of CO2 retention (e.g. chronic obstructive pulmonary disease)

- Patients who are receiving radiotherapy or chemotherapy when registering for the
study or who plan to receive it during the study

- Patient who are pregnant or are of childbearing potential and not using
contraceptives